C07K 14/8128
Antithrombin iii
Official title: {Antithrombin III}
C07K14/8128 (Antithrombin iii) appears on 59 US grants and 51 published applications in this corpus.
Search patents in C07K- Granted patents
- 59
- Published applications
- 51
- Assignees
- 61
- Inventors
- 153
- Latest grant
- 7 Dec 2021
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1978 | 1 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 2 | 0 |
| 1982 | 1 | 0 |
| 1983 | 1 | 0 |
| 1984 | 2 | 0 |
| 1985 | 3 | 0 |
| 1986 | 1 | 0 |
| 1987 | 1 | 0 |
| 1988 | 1 | 0 |
| 1989 | 0 | 0 |
| 1990 | 1 | 0 |
| 1991 | 1 | 0 |
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 1 | 0 |
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 2 | 0 |
| 1998 | 1 | 0 |
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 3 |
| 2002 | 5 | 4 |
| 2003 | 1 | 3 |
| 2004 | 3 | 0 |
| 2005 | 2 | 4 |
| 2006 | 4 | 3 |
| 2007 | 0 | 4 |
| 2008 | 0 | 2 |
| 2009 | 1 | 1 |
| 2010 | 1 | 4 |
| 2011 | 3 | 1 |
| 2012 | 1 | 2 |
| 2013 | 2 | 2 |
| 2014 | 3 | 4 |
| 2015 | 2 | 1 |
| 2016 | 3 | 2 |
| 2017 | 1 | 3 |
| 2018 | 1 | 0 |
| 2019 | 1 | 1 |
| 2020 | 2 | 1 |
| 2021 | 1 | 2 |
| 2022 | 0 | 1 |
| 2023 | 0 | 0 |
| 2024 | 0 | 0 |
| 2025 | 0 | 2 |
| 2026 | 0 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Treatment of infection by human enterovirus D687 Dec 2021US 11,191,817 B2AnsunBiopharma, Inc.
- Methods for detecting levels of pigment epithelium-derived factor and antithrombin-III for characterising and/or prognosing prostate cancer17 Nov 2020US 10,837,965 B2University College Dublin, National University of Ireland
- Class of therapeutic protein based molecules7 Jan 2020US 10,525,109 B2Ansun Biopharma, Inc.
- Treatment of infection by human enterovirus D6825 Jun 2019US 10,328,128 B2Ansun Biopharma, Inc.
- Pre-treatment agent and pre-treatment method for antithrombin III to be subjected to limulus test20 Nov 2018US 10,132,812 B2Seikagaku Corporation
- Antithrombin in stroke22 Jan 2026US 2026/0022158 A1Grifols Worldwide Operations Limited
- Improved anti-albumin nanobodies and their uses25 Dec 2025US 2025/0388663 A1Institut National de la Sante et de la Recherche Medicale
- Plasma fractionation utilizing spray-dried human plasma6 Nov 2025US 2025/0340588 A1Takeda Pharmaceutical Company Limited
- Plasma fractionation utilizing spray-dried human plasma7 Apr 2022US 2022/0106357 A1Takeda Pharmaceutical Company Limited
- Gene editing of anticoagulants14 Oct 2021US 2021/0317448 A1Toolgen Incorporated
Most cited
By later US patents
- Blood coagulation factors and process for their manufacture135US 4,297,344 ABehringwerke Aktiengesellschaft · 1981
- Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders57US 6,818,439 B1Chiron Corporation · 2004
- Compositions and method for regulating apoptosis46US 6,992,063 B2The Trustees of Princeton University · 2006
- Material for affinity chromatography which is a sulfated polysaccharide bonded to an insoluble polymer38US 5,116,962 ABehringwerke Aktiengesellschaft · 1992
- Fractionating citrate-stabilized plasma30US 4,272,523 ABiotest-Serum-Institut GmbH · 1981